The global rheumatoid arthritis drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are expected to accelerate the growth of the market include a rise in prevalence of rheumatoid arthritis, expiration of patents & the entry of biosimilar drugs, the surge in geriatric population, increase in adoption of conventional DMARDs, and government initiatives toward spread in awareness for rheumatoid arthritis symptoms. Moreover, innovations in advanced biologics are further anticipated to fuel the growth of the market. Furthermore, a rise in focus associated with early screening and treatment of rheumatoid arthritis is expected to offer high growth potential for the market during the forecast period.

Rheumatoid arthritis is a disorder that causes pain and inflammation in joints. It affects individuals of all ages; however, the geriatric population is highly at risk of affected with this disease. The symptoms of rheumatoid arthritis consist of pain, stiffness, tenderness, and swelling of joints. Currently, no cure is available for rheumatoid arthritis. However, certain drugs are used to efficaciously control the conditions of rheumatoid arthritis, which include disease-modifying anti-rheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and uric acid drugs. According to the Lancet Rheumatology 2020, patients with rheumatoid arthritis who develop COVID-19 infection may be at high risk for developing severe symptoms and additional complications. Some DMARDs that are commonly used to treat rheumatoid arthritis, such as hydroxychloroquine drug, are being investigated as potential therapy for COVID-19. Moreover, other generally used therapies such as biologics targeting interleukin (IL)-6 (sarilumab, tocilizumab) and IL-1 (anakinra) are being assessed in patients with COVID-19. Thus, COVID-19 infection uplifted growth opportunities for manufacturers of rheumatoid arthritis drugs.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Drug Type 

o By Distribution Channel

o By Application 

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

Competitive Landscape: AbbVie Inc., Amgen Inc., and Bristol-Myers Squibb Company, among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Rheumatoid Arthritis Drugs Market Report by Segment

By Drug Type

• Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
• Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
• Corticosteroids
• Biologic Response Modifiers (Biologics)

By Distribution Channel

• Hard Shelled Capsules 
• Soft Shelled Capsules 

By Application

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Rheumatoid Arthritis Drugs Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa